
BCTX Stock Forecast & Price Target
BCTX Analyst Ratings
Bulls say
BriaCell Therapeutics Corp has received a significant non-dilutive grant of $2 million from the US National Cancer Institute to advance its Bria-PROS+ program toward clinical stages, specifically to support manufacturing and Phase 1/2a development in metastatic prostate cancer. This funding not only underscores the potential of BriaCell's innovative immunotherapy programs but also enables accelerated clinical development of Bria-OTS+, which builds upon the existing Bria-OTS program currently in a Phase 1/2 clinical trial. The combination of financial backing and ongoing clinical advancements positions BriaCell favorably within the biotechnology sector, particularly in the highly challenging field of cancer immunotherapy.
Bears say
BriaCell Therapeutics faces significant risks that contribute to a negative financial outlook, including potential safety signals emerging from clinical trials and the possibility of lower-than-expected efficacy, which could undermine the success of its immunotherapy programs. The company also grapples with heightened commercial competition and regulatory uncertainties that may impact its market position and ability to bring products to market. Additionally, the estimated need for approximately $120 million in further financing by 2037, combined with ongoing capital requirements, raises concerns about the company’s financial stability and long-term viability.
This aggregate rating is based on analysts' research of BriaCell Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BCTX Analyst Forecast & Price Prediction
Start investing in BCTX
Order type
Buy in
Order amount
Est. shares
0 shares